ClinicalTrials.gg
TerminatedNCT03307993Updated Apr 4, 2018

Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease

A Phase 1 interventional study of Idalopirdine in Alzheimer's Disease, sponsored by H. Lundbeck A/S. Terminated at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-04-04.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated for strategic reasons.

From the registry’s dates

  • Primary completion was Feb 2018, 8 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Alzheimer Disease by H. Lundbeck A/S — none open to participants now, none under way, none of them phase 3. Alzheimer Disease · H. Lundbeck A/S.

Enrollment
15th of 16
3 · median 278
Started
2017
the only one that year
Phase 1
6 of 16
none open now
Registered
13th of 16
by date

Among the 16 studies in Alzheimer Disease by H. Lundbeck A/S, this one is the 15th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 1, and was the 13th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

None of the 16 studies in Alzheimer Disease by H. Lundbeck A/S is open now. The open studies under Alzheimer Disease, anywhere →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Alzheimer Disease by H. Lundbeck A/S as a file.
02

Study summary

To investigate the brain receptor occupancy of idalopirdine in patients with Alzheimer's disease (AD)

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Lu AE58054
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has probable AD diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) criteria.
  • The patient has had a positive amyloid PET scan, which in the opinion of the principal investigator is consistent with a diagnosis of AD.
  • The patient has a (MMSE) score at screening of at least 15 and no greater than 22.
  • The patient has a knowledgeable and reliable caregiver who will accompany the patient to all clinic visits during the study and answer questions about the patient.
  • The patient is a man or woman of at least 50 years of age and has a (BMI) ≥ 18.5 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • The patient has evidence of any neurodegenerative disease, or other serious neurological disorders other than AD including but not limited to Lewy body dementia, fronto-temporal dementia, Parkinson's disease, Huntington's disease, major cortical stroke, major head trauma, primary or secondary cerebral neoplasia or systemic medical diseases that are, in the investigator's opinion, likely to affect central nervous system functioning and may influence the outcome or analysis of the scan results.
  • The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Idalopirdine

    Idalopirdine 60 mg once daily for 10 day (up to 14 days possible), adjunct to donezepil (patients individualized maintenance dose) If high receptor occupancy cannot be verified, the receptor occupancy following a higher dose (up to 60 mg twice daily for 10-14 days) will be assessed in Cohort 2.

    Drug: Idalopirdine

Interventions

  • Idalopirdine 60-120 mg daily dose

    Also known as: Lu AE58054

06

What researchers measure

Primary outcomes

  1. 5-HT6 Receptor Occupancy (RO)

    RO in the region of interest will be calculated as 100 × (1 - BPND(treatment) / BPND(baseline)) where BPND is the binding potential

    Time frame: Treatment day 10 (24 hours post dose)

  2. Idalopirdine plasma concentration (CPET)

    CPET is the concentration at the time of PET scan, defined as (CprePET + CpostPET) / 2 (average of the pre- and post-PET scanning measurements).

    Time frame: Prior to and after PET scan on treatment day 10

07

Study locations

1 site
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Feb 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2017
First posted
Oct 12, 2017
StartActual
Sep 22, 2017
Primary completionActual
Feb 19, 2018
CompletionActual
Feb 19, 2018
Last update
Apr 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03307993
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Oct 12, 2017
Start date
Sep 22, 2017
Primary completion
Feb 19, 2018
Completion
Feb 19, 2018
Last update
Apr 4, 2018

Study contacts

Email contact via H. Lundbeck A/S
study director · H. Lundbeck A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idalopirdine

Start the discussion